U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07077161) titled 'Cabozantinib Dose Skipping as an Alternative to Dose Reductions' on July 08.
Brief Summary: The goal of this study is to determine if an alternative cabozantinib dosing regimens results in a similar drug exposure compared to the standard regimens in patients with metastatic renal cell carcinoma (mRCC). All dosages of cabozantinib (20 ,40, 60mg) have the same price, and cabozantinib is eliminated very slowly by the body. This means that using fewer tablets could potentially lead to cost savings, while remaining equally effective.
The main questions it aims to answer are:
* Is the drug exposure from our experimental regimens similar...